Navigation Links
Faruqi & Faruqi, LLP is Investigating Peregrine Pharmaceuticals Inc. on Behalf of its Shareholders - PPHM
Date:4/9/2013

mplement corporate governance measures designed to prevent future misconduct should contact the firm.

Request more information now by clicking here: www.faruqilaw.com/Peregrine.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action and derivative litigation.  The firm is focused on providing exemplary legal services in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation.  The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients.

If you hold PPHM shares and you would like to discuss your legal rights, visit www.faruqilaw.com/Peregrine.  You can also contact us by calling Michael J. Hynes free at 877-247-4292 or at 215-277-5770 or by sending an e-mail to mhynes@faruqilaw.com.

Contact:

Faruqi & Faruqi, LLP
Michael J. Hynes, Esq.
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Telephone: (877) 247-4292 or (215) 277-5770
E-mail: mhynes@faruqilaw.com

(NASDAQ: PPHM)

Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
2. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
3. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
4. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In American Oriental Bioengineering Inc. To Contact The Firm Regarding The August 22, 2012 Lead Plaintiff Deadline
6. Faruqi & Faruqi, LLP is Investigating AmerisourceBergen Corporation on Behalf of its Shareholders
7. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
8. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
9. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
10. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015 BioLineRx ... clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and ... has commenced an underwritten public offering of American ... its Ordinary Shares. All of the ADSs in ... JMP Securities is acting as ...
(Date:3/5/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... therapeutics including high value and difficult to manufacture ... full year 2014 financial results will be released ... opens for trading.  At 9:00 am Eastern Time, ... discuss the financial results and provide a business ...
(Date:3/5/2015)... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, with operations ... financial results for the fourth quarter and full year ... Net Revenues Increased 21.3% Year Over Year to $190.6 ... Year Over Year to $140.5 Million , Manufacturing ...
Breaking Medicine Technology:BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3Pfenex To Report Fourth Quarter and Full Year 2014 Results and Provide Business Update 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22
... ABBOTT PARK, Ill., March 11 The ... review the supplemental new drug application (sNDA) of a ... Depot (leuprolide acetate for depot ... prostate cancer.  Palliative treatment helps to relieve symptoms associated ...
... HARBIN, China , March 11 /PRNewswire-Asia-FirstCall/ -- ... a,developer, manufacturer and distributor of botanical products,bio-pharmaceuticals and traditional ... its Shengmai Granules price by 12%. Shengmai,Granule is an ... ...
Cached Medicine Technology:Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 2Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 3Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 4Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 5Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 6Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 7Renhuang Announces Price Increase on Shengmai Granules 2Renhuang Announces Price Increase on Shengmai Granules 3Renhuang Announces Price Increase on Shengmai Granules 4
(Date:3/5/2015)... Shania Twain will be touring throughout North ... She has hinted that this will be her final tour and ... last time. She has had a residency in Las Vegas ... millions of loyal fans around the world. After opening in ... on June 30th she will be at Madison Square Garden (MSG) ...
(Date:3/5/2015)... San Diego, CA (PRWEB) March 05, 2015 ... dangerous levels of formaldehyde in low-cost laminate ... Bamboo, the leading manufacturer of eco-friendly building materials ... to customer safety by testing all their flooring ... leading emissions detection laboratory Benchmark International ...
(Date:3/5/2015)... 2015 A Bakersfield, Calif. state court jury ... trial awarding the plaintiff Coleen M. Perry a total of ... a TVT-Abbrevo pelvic mesh sling device, manufactured by Ethicon, Inc., ... , a partner at Wagstaff & Cartmell in ... plaintiff, along with Rich Freese and Tim Goss of ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 AxoGen, ... focused on the peripheral nerve repair market, reported record ... December 31, 2014 compared to $2.98 million in the ... its growth strategies. , “Our strong fourth quarter ... peripheral nerve repair products which is driving increased surgeon ...
(Date:3/5/2015)... 2015 Risperdal lawsuits ( http://www.risperdallawsuit2014.com/ ... mass tort litigation currently underway in the Philadelphia ... begun hearing testimony in the proceeding’s second bellwether ... can cause gynecomastia, or male breast growth. According ... filed on behalf of a plaintiff who was ...
Breaking Medicine News(10 mins):Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 2Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3
... Nashville ... Dental Association (NDA) at 6 p.m. on December 5 at the Loews Vanderbilt Plaza Hotel ... Nashville, Tenn. ... the 86th president of the National Dental Association (NDA) at 6 p.m. on December 5 ...
... ... N.Y. Times #1 best-seller KNOCKOUT , ... Cornwall, NY (PRWEB) December 2, 2009 -- In her new book KNOCKOUT, Interviews ... Place, Suzanne Somers interviews doctors who are successfully using the most innovative cancer treatments--treatments that ...
... ... released his first full-length book, Short White Coat: Lessons from Patients on Becoming a Doctor, ... , ... December 2, 2009 -- Most people will, at some point or another, either find themselves ...
... , CAMPBELL, Calif., Dec. ... Dr. Rafael Pelayo, Associate Professor at the Stanford Sleep Disorders Clinic ... Sound Machine as part of a healthy sleep plan for people ... drugs. , "Background noise is a problem for people when they ...
... CHICAGO, Dec. 2 A randomized, controlled study comparing standard ... decompression for painful herniated disc revealed that while both treatments ... patients pain free up to two years later. Results of ... at the annual meeting of the Radiological Society of North ...
... , SEATTLE, Dec. 2 ... that Ruth Pettengell, M.D. of St. George,s Hospital, University of ... will present new data on the pixantrone phase III trial ... Meeting of the American Society of Hematology on Saturday, December ...
Cached Medicine News:Health News:Meharry Medical College Officer Will Head the National Dental Association 2Health News:Meharry Medical College Officer Will Head the National Dental Association 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 2Health News:Innovative Biofeedback Technology Wins By A "Knockout." 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 4Health News:Beneath the Short White Coat: A Medical Student Reveals All 2Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 2Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 3Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 3Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 2Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 3Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 4
Alexander periosteal elevators....
Lambotte periosteal elevators....
Cottle periosteal & skin elevator, 7 1/2", slightly curved blade, 9 mm wide....
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Medicine Products: